Recipient: Dr Michelle Henderson
Institute: University of NSW
Funding: $138,179 July 2019 to June 2022
Rapidly dividing cancer cells can be dependent on a cellular biochemical called nicotinamide adenine dinucleotide (NAD) as an energy source.

While survival rates for paediatric acute lymphoblastic leukaemia (ALL) have improved dramatically over recent decades, the outlook for certain subgroups remains dismal. These include children where treatment fails, those who relapse during treatment, or whose leukaemia harbours genetic abnormalities – something that commonly occurs in infant ALL and is referred to as MLL-R leukaemia.
 
New, more specific therapeutic agents, tailored to patient needs are urgently needed.
 
Together with colleagues in the United States, the Henderson lab discovered and developed OT-82, a new drug that blocks the production of NAD and has remarkably strong anti-leukaemia activity, even against the most aggressive subtypes of leukaemia.
 
Over three years, this research project aims to further develop this drug so it then can be tested as a viable therapeutic strategy for aggressive leukaemia in children, to ultimately improve their survival and minimise the side effects of treatment.

This project recieved further support through Cancer Australia's Priority-driven Collaborative Cancer Research Scheme.
Science is the solution for kids with cancer
The only way to improve outcomes for children diagnosed with cancer is through advances in medical research. Every day and every donation takes us closer to a cure.
Select your donation details
Please enter the amount you would like to donate

The Kids' Cancer Project is an ACNC Registered Charity 
ABN 13 061 138 181 | CFN 10581